# Choroidal Neovascularization Market > Choroidal Neovascularization Market Research Report By Treatment Type (Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium), By Indication (Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications), By Route of Administration (Intravitreal, Subconjunctival, Periocular, Oral), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.64% - **2024:** $ 1.92 Billion - **2025:** $ 2.04 Billion - **2035:** $ 3.89 Billion - **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer(US), Amgen (US), Santen Pharmaceutical (JP), Eyenovia (US) **Report ID:** MRFR/HC/25867-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/choroidal-neovascularization-market-27541 --- ## Market Summary ## **Choroidal Neovascularization Market Overview** As per MRFR analysis, the Choroidal Neovascularization Market Size was estimated at 1.92 (USD Billion) in 2024. The Choroidal Neovascularization Market Industry is expected to grow from 2.04 (USD Billion) in 2025 to 3.65 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.64% during the forecast period (2025 - 2034). ### **Key Choroidal Neovascularization Market Trends Highlighted** The global choroidal neovascularization (CNV) market is experiencing significant growth, driven by advancements in treatment options and the increasing prevalence of age-related macular degeneration (AMD), a major cause of CNV. Recent trends include the emergence of intravitreal anti-VEGF therapies, and gene therapy approaches, offering improved efficacy and reduced treatment burden. Moreover, the growing adoption of optical coherence tomography angiography (OCTA) for early detection and monitoring of CNV is enhancing diagnostic capabilities and facilitating timely intervention. Opportunities lie in the development of combination therapies, personalized treatment strategies based on genetic profiles, and the exploration of novel targets for CNV inhibition. With these advancements, the market for CNV management is expected to witness continued growth in the coming years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Choroidal Neovascularization Market Drivers** ### Increasing Prevalence of Age-Related Macular Degeneration (AMD) Age-related macular degeneration is one of the widespread causes of vision loss in people over 50. It is a prevailing condition among individuals where the macula, the center part of the retina that is responsible for sharp central vision, deteriorates. Choroidal neovascularization is the growth of abnormal blood vessels emerging beneath the macula. It appears in almost 10-15% of patients with AMD. It is associated with leakage of fluids and blood, scarring among improper perfused vessels, and may cause visionary damage. The growing amount of age-related macular degeneration cases is a vital stimulant of the Choroidal Neovascularization Market. ### Technological Advancements in Diagnostic and Therapeutic Options Technological advancements have been vital in the diagnosis and treatment of choroidal neovascularization. Optical coherence tomography and fluorescein angiography are some of the imaging methods commonly employed in Choroidal Neovascularization (CNV). Consequently, the Optometrist can visualize CNV and keep track of its development. Moreover, Anti-vascular endothelial growth factor has transformed CNV’s treatment. Anti-vascular Endothelial Growth Factor drugs can block VEGF, a protein that incites more blood vessels to grow, from working, thus decreasing the amount of leakage and improving vision. Hence, the Market will expand because of fresh and more effective diagnostic and therapeutic options. ## Rising Healthcare Expenditure and Government Support The Choroidal Neovascularization Market is growing due to rising healthcare expenditure and government support. The expenditure on health is growing, which is expected to drive the demand for new and advanced treatments for diseases. In addition, governments of many countries are increasing their spending on eye care and research and development. This will result in the development of new treatments and technology for helping patients suffering from choroidal neovascularization. ## **Choroidal Neovascularization Market Segment Insights** ### **Choroidal Neovascularization Market Treatment Type Insights** The Choroidal Neovascularization Market is segmented by Treatment Type into Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, and Pegaptanib Sodium. Anti-Angiogenic Therapy is expected to hold the largest market share in the Choroidal Neovascularization Market due to its effectiveness in preventing the growth of new blood vessels that supply the choroidal neovascularization. One of the other widely used treatments in the market is the Laser Photocoagulation, which involves destroying the choroidal neovascularization with the use of a laser. Photodynamic Therapy is one of the minimally invasive treatment options available in the market, which employs a light-activated drug for destroying choroidal neovascularization. Verteporfin Sodium is a photosensitizing agent used in Photodynamic Therapy. Ranibizumab, Bevacizumab, and Aflibercept are the anti-VEGF agents that are approved for the treatment of choroidal neovascularization. Pegaptanib Sodium is the other anti-VEGF agent used for the treatment of choroidal neovascularization. The Choroidal Neovascularization Market is expected to grow in the coming years due to the increasing prevalence of age-related macular degeneration. The other major proven cause of choroidal neovascularization is angioid streaks that are caused by the side effects of pseudoexfoliation syndrome. The key drivers are the rising use of advanced treatments like anti-aging therapy and Photodynamic Therapy. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Choroidal Neovascularization Market Indication Insights** The Choroidal Neovascularization Market segmentation by Indication comprises Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), and Other Indications. Among these, AMD is expected to hold the largest market share due to its high prevalence and increasing geriatric population. DME is another major indication driven by the rising incidence of diabetes worldwide. CSC and PCV are also significant contributors to the market, with growing awareness and advancements in treatment options. The "Other Indications" segment includes conditions such as ocular histoplasmosis syndrome, angioid streaks, and presumed ocular histoplasmosis syndrome, which collectively account for a smaller market share. ### **Choroidal Neovascularization Market Route of Administration Insights** The Choroidal Neovascularization Market is segmented by Route of Administration into Intravitreal, Subconjunctival, Periocular, and Oral. Among these, the Intravitreal segment held the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. This is attributed to the high efficacy and tolerability of intravitreal injections for treating choroidal neovascularization. The Subconjunctival segment is projected to register the highest CAGR during the forecast period, owing to the increasing adoption of sustained-release subconjunctival implants for long-term drug delivery. The Periocular and Oral segments are expected to witness moderate growth over the forecast period. ### **Choroidal Neovascularization Market End User Insights** The End User segment of the Choroidal Neovascularization Market is expected to exhibit significant growth in the coming years. Hospitals are anticipated to dominate the market, owing to factors such as the increasing number of patients seeking treatment for choroidal neovascularization, the availability of advanced diagnostic and treatment facilities, and the presence of skilled healthcare professionals in these settings. Furthermore, the growing adoption of minimally invasive procedures, such as anti-VEGF injections and laser therapy, is contributing to market growth. Ophthalmology clinics are projected to witness a substantial market share due to their specialized services and expertise in treating eye disorders. Ambulatory surgical centers are expected to gain traction as they offer convenience and cost-effective treatment options for patients. Research centers play a crucial role in advancing the understanding of choroidal neovascularization and developing novel treatment modalities. Their contributions to clinical trials and research studies are expected to drive market growth in the future. ### **Choroidal Neovascularization Market Regional Insights** The regional landscape of the Choroidal Neovascularization Market showcases distinct growth trajectories across key regions. North America dominates the market with a significant revenue share, driven by factors such as the rising prevalence of age-related macular degeneration, advanced healthcare infrastructure, and increasing adoption of novel therapies. Europe follows closely, with a substantial market presence fueled by government initiatives, reimbursement policies, and a growing aging population. The Asia-Pacific (APAC) region is poised for substantial growth, attributed to a large patient pool, increasing healthcare expenditure, and the emergence of local manufacturers. South America and the Middle East and Africa (MEA) regions are expected to witness steady growth, driven by government initiatives and increasing awareness about choroidal neovascularization. These regional insights provide valuable information for market players to tailor their strategies and target specific geographies for growth and expansion. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Choroidal Neovascularization Market Key Players and Competitive Insights** The major players in the Choroidal Neovascularization Market are focused continuously on the development of novel therapeutic approaches to address the unmet medical needs of patients with CNV. Leading Choroidal Neovascularization Market players are involved in clinical trials, research collaborations, and strategic partnerships to fortify their product portfolios and expand their market presence. The competitive Choroidal Neovascularization Market landscape is a mix of both established pharmaceutical companies and emerging biotechnology ventures. Novartis, Bayer, Roche, Regeneron, and Allergan are the key players in the Choroidal Neovascularization Market. These companies are spending on research and development activities to develop innovative therapies targeting the underlying cause of CNV and improve patient outcomes. The Choroidal Neovascularization Market has excellent growth potential in the upcoming years due to the growing prevalence of age-related macular degeneration and diabetic retinopathy and the development of novel therapeutic approaches. Novartis is one of the leading players in the Choroidal Neovascularization Market with a strong presence in ophthalmology. The company’s present portfolio includes Lucentis ranibizumab, which is a VEGF inhibitor approved for the treatment of wet age-related macular degeneration and other retinal diseases. Novartis has a robust pipeline of new therapies for CNV, including brolucizumab, a new drug showing superior effects in clinical trials. This new drug is also a strong contender for a blockbuster position in the near future. Novartis’ POS is high due to its strong commercial presence and commitment to innovation. Bayer is another prominent player in the Choroidal Neovascularization Market with a stronghold in ophthalmology. The company’s present portfolio includes Eylea aflibercept, a VEGF inhibitor approved for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other retinal diseases. The company's current drug being developed for CNV is farcical. The biggest strength of Bayer in the Choroidal Neovascularization Market is its strong product portfolio and commitment to Research and Development. ### **Key Companies in the Choroidal Neovascularization Market Include** ### **Choroidal Neovascularization Market Developments** Key factors driving this growth include the increasing prevalence of age-related macular degeneration (AMD), the leading cause of CNV, as well as advancements in treatment modalities such as anti-vascular endothelial growth factor (VEGF) therapies. Geographic regions with high geriatric populations, such as North America and Europe, are expected to hold significant market shares. Recent developments in the CNV market include the approval of novel anti-VEGF agents with improved efficacy and safety profiles, as well as the emergence of gene therapy approaches targeting the underlying genetic causes of CNV. ## **Choroidal Neovascularization Market Segmentation Insights** ### **Choroidal Neovascularization Market Treatment Type Outlook** ### **Choroidal Neovascularization Market Indication Outlook** ### **Choroidal Neovascularization Market Route of Administration Outlook** ### **Choroidal Neovascularization Market End User Outlook** ### **Choroidal Neovascularization Market Regional Outlook** ## Market Drivers ### Rising Prevalence of Eye Disorders The increasing incidence of eye disorders, particularly age-related macular degeneration (AMD), is a primary driver of the Choroidal Neovascularization Market. As populations age, the prevalence of AMD and other retinal diseases rises, leading to a greater demand for effective treatment options. According to recent estimates, AMD affects millions worldwide, with projections indicating that the number of affected individuals could reach 288 million by 2040. This surge in cases necessitates innovative therapies and interventions, thereby propelling the growth of the Choroidal Neovascularization Market. Furthermore, the growing awareness of eye health and the importance of early diagnosis contribute to the rising demand for specialized treatments, creating a robust market environment for stakeholders involved in this sector. ### Advancements in Diagnostic Technologies Technological advancements in diagnostic tools are significantly influencing the Choroidal Neovascularization Market. Enhanced imaging techniques, such as optical coherence tomography (OCT) and fundus photography, allow for earlier and more accurate detection of choroidal neovascularization. These innovations facilitate timely intervention, which is crucial for improving patient outcomes. The market for diagnostic devices is projected to grow, with estimates suggesting a compound annual growth rate (CAGR) of over 6% in the coming years. As healthcare providers increasingly adopt these advanced diagnostic technologies, the demand for subsequent therapeutic interventions is likely to rise, further stimulating the Choroidal Neovascularization Market. This trend underscores the importance of integrating cutting-edge technology into clinical practice to enhance patient care. ### Growing Awareness and Education Initiatives The rise in awareness and education initiatives regarding eye health is a crucial driver for the Choroidal Neovascularization Market. Organizations and healthcare providers are increasingly focusing on educating the public about the risks associated with retinal diseases and the importance of regular eye examinations. This heightened awareness is likely to lead to earlier diagnosis and treatment of choroidal neovascularization, thereby expanding the market. Campaigns aimed at promoting eye health have shown positive results, with surveys indicating that individuals who are informed about eye conditions are more likely to seek medical advice. Consequently, this trend is expected to bolster the demand for therapies and interventions within the Choroidal Neovascularization Market, creating a more informed patient population. ### Regulatory Support for Innovative Treatments Regulatory bodies are increasingly providing support for the development and approval of innovative treatments within the Choroidal Neovascularization Market. Initiatives aimed at expediting the review process for new therapies, such as breakthrough therapy designations and fast-track approvals, are encouraging pharmaceutical companies to invest in the development of novel solutions. This regulatory environment fosters innovation and enhances the availability of effective treatments for patients suffering from choroidal neovascularization. Recent data suggests that the approval timelines for new ophthalmic drugs have decreased, allowing for quicker access to therapies. As regulatory support continues to evolve, it is likely to stimulate growth in the Choroidal Neovascularization Market, ultimately benefiting patients and healthcare providers. ### Increased Investment in Research and Development The Choroidal Neovascularization Market is experiencing a surge in investment directed towards research and development (R&D) initiatives. Pharmaceutical companies and biotechnology firms are allocating substantial resources to discover and develop novel therapies targeting choroidal neovascularization. This focus on R&D is driven by the need for more effective treatments that can address the underlying causes of retinal diseases. Recent reports indicate that global spending on R&D in the pharmaceutical sector has reached approximately 200 billion, with a significant portion dedicated to ophthalmic research. As new therapies emerge from these investments, they are expected to enhance treatment options available in the Choroidal Neovascularization Market, ultimately benefiting patients and healthcare providers alike. ## Future Outlook The Choroidal Neovascularization Market is projected to grow at a 6.64% CAGR from 2025 to 2035, driven by advancements in treatment modalities and increasing prevalence of age-related macular degeneration. **New opportunities:** - Development of targeted gene therapies for enhanced treatment efficacy. Expansion of telemedicine platforms for remote patient monitoring. Investment in AI-driven diagnostic tools to improve early detection. By 2035, the Choroidal Neovascularization Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Treatment Type: Anti-Angiogenic Therapy (Largest) vs. Photodynamic Therapy (Fastest-Growing) In the Choroidal Neovascularization Market, the distribution of market share among various treatment types is indicative of the growing importance of specific therapies. Anti-angiogenic therapy, including agents like Ranibizumab, Aflibercept, and Bevacizumab, holds the largest share due to its effectiveness in managing neovascular age-related macular degeneration. Conversely, treatments such as Laser Photocoagulation and Photodynamic Therapy are prevalent yet represent a smaller portion of the Choroidal Neovascularization Market as they become less favorable compared to advanced anti-angiogenic options. Anti-Angiogenic Therapy (Dominant) vs. Photodynamic Therapy (Emerging) Anti-angiogenic therapies are at the forefront of the treatment landscape for choroidal neovascularization, particularly Ranibizumab and Aflibercept, which are recognized for their ability to inhibit neovascularization effectively. These therapies are widely adopted due to their proven results in improving vision and stabilizing choroidal neovascularization. On the other hand, Photodynamic Therapy, including Verteporfin Sodium, is considered an emerging treatment modality. Although it shows promise in specific patient populations, its market position is hindered by the dominance of newer anti-angiogenic agents. Nevertheless, ongoing research and clinical trials may enhance its adoption, reflecting a potential shift in preference among healthcare providers. ### By Indication: Age-Related Macular Degeneration (AMD) (Largest) vs. Diabetic Macular Edema (DME) (Fastest-Growing) The Choroidal Neovascularization Market is characterized by significant diversity across its indications, with Age-Related Macular Degeneration (AMD) capturing the largest market share. This segment has consistently demonstrated its dominance, driven by a growing elderly population and increased awareness of eye diseases. Following closely is Diabetic Macular Edema (DME), which is emerging rapidly due to rising diabetes prevalence, showcasing a growing segment that is gaining traction in therapeutic advancements. Furthermore, Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), and Myopic Macular Degeneration (MMD) contribute to the overall market dynamics, albeit at a smaller scale. The growth trends indicate a shift towards innovative treatment options, with current research focusing on personalized medicine. Novel therapies improving patient outcomes are anticipated to drive the Choroidal Neovascularization Market, particularly in indications like DME, where treatment advancements are expected to address unmet medical needs. AMD (Dominant) vs. DME (Emerging) Age-Related Macular Degeneration (AMD) stands out as the dominant indication in the Choroidal Neovascularization Market, primarily due to its widespread prevalence among the aging population. This indication significantly shapes market strategies, with numerous pharmaceutical companies focusing their R&D efforts on developing novel therapies and interventions specifically targeting AMD. On the other hand, Diabetic Macular Edema (DME) is recognized as an emerging force within the market, fueled by the increasing incidence of diabetes globally. The therapeutic landscape for DME is evolving, with innovative treatments being introduced that enhance visual outcomes and manage disease progression. The juxtaposition of AMD's established market presence with DME's rapid growth creates a dynamic environment in the Choroidal Neovascularization Market. ### By Route of Administration: Intravitreal (Largest) vs. Subconjunctival (Fastest-Growing) In the Choroidal Neovascularization Market, the Route of Administration segment showcases Intravitreal as the largest contributor, commanding a substantial share. This method allows for direct delivery of therapeutic agents to the vitreous humor, optimizing treatment efficacy for patients. In contrast, Subconjunctival administration, while smaller in market size, is rapidly gaining traction due to its minimal invasiveness and patient compliance benefits. As healthcare providers seek more patient-friendly options, Subconjunctival injections are positioned for significant growth. Intravitreal (Dominant) vs. Subconjunctival (Emerging) Intravitreal administration remains the dominant route in treating Choroidal Neovascularization Market, primarily due to its targeted delivery mechanism that directly addresses the affected area, resulting in rapid onset of action. This method is particularly favored for its effectiveness in delivering biological agents like monoclonal antibodies. Conversely, Subconjunctival administration is emerging as a favorable alternative, offering advantages such as lower patient discomfort and ease of administration. With ongoing advancements in drug formulations and techniques, Subconjunctival methods are likely to witness increased adoption, appealing to both physicians and patients looking for less invasive treatment options. ### By End User: Hospitals (Largest) vs. Ophthalmology Clinics (Fastest-Growing) In the Choroidal Neovascularization Market, hospitals represent the largest end user segment, largely due to their comprehensive treatment capabilities and advanced facilities. They are well-equipped to handle a high volume of complex cases, which contributes significantly to their market share. Conversely, ophthalmology clinics, while smaller in market share, are rapidly gaining traction. Their specialized focus on eye health enables them to provide tailored services, making them increasingly popular among patients seeking specific treatments for conditions like choroidal neovascularization. Ophthalmology Clinics: Emerging vs. Research Centers: Dominant Ophthalmology clinics have emerged as a vital player in the Choroidal Neovascularization Market, offering focused and specialized treatment solutions that cater to patients' specific needs. These clinics are often more agile in adopting new technologies and treatment methodologies, which appeals to a growing patient base seeking cutting-edge care. In contrast, research centers hold a dominant position by driving innovation and conducting pivotal studies in the field. Their contributions to understanding disease mechanisms and developing new therapies position them as essential players in shaping future treatment paradigms. ## Regional Market Share Analysis ### North America : Leading Innovation and Research North America is the largest market for Choroidal Neovascularization Market (CNV) treatments, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of age-related macular degeneration, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring timely approvals for innovative therapies. The United States is the primary contributor, with key players such as Regeneron Pharmaceuticals and Pfizer leading the charge. Canada also plays a significant role, albeit smaller, focusing on expanding access to treatments. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech firms, all vying for market share in this lucrative sector. ### Europe : Regulatory Framework and Growth Europe is the second-largest market for Choroidal Neovascularization Market, accounting for approximately 30% of the global market share. The region's growth is driven by increasing awareness of eye diseases, advancements in treatment options, and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of new therapies, which enhances patient access to innovative treatments. Leading countries include Germany, France, and the UK, where healthcare systems are increasingly adopting new technologies. Major players like Novartis and Roche are actively involved in research and development, contributing to a competitive landscape that fosters innovation. The presence of numerous clinical trials further indicates a robust pipeline of potential therapies aimed at addressing CNV. ### Asia-Pacific : Emerging Market Potential The Asia-Pacific region is witnessing rapid growth in the Choroidal Neovascularization Market, driven by increasing healthcare expenditure and rising awareness of eye health. This region holds approximately 20% of the global market share, with countries like Japan and China leading the charge. The growing elderly population and the prevalence of chronic diseases are significant factors contributing to market expansion, alongside supportive government initiatives aimed at improving healthcare access. Japan is a key player, with companies like Santen Pharmaceutical making strides in innovative treatments. China is also emerging as a significant market, with increasing investments in healthcare infrastructure. The competitive landscape is evolving, with both local and international players vying for market presence, indicating a promising future for CNV treatments in this region. ### Middle East and Africa : Untapped Market Potential The Middle East and Africa (MEA) region represents an emerging market for Choroidal Neovascularization Market treatments, holding about 5% of the global market share. The growth in this region is primarily driven by increasing healthcare investments and a rising prevalence of eye diseases. Governments are focusing on enhancing healthcare infrastructure, which is expected to catalyze market growth in the coming years, despite existing challenges such as limited access to advanced therapies. Countries like South Africa and the UAE are leading the way in adopting new treatment modalities. The competitive landscape is characterized by a mix of local and international players, with companies exploring partnerships to enhance their market presence. As awareness of CNV grows, the potential for market expansion in this region is significant, paving the way for innovative solutions. ## Competitive Benchmarking The major players in the Choroidal Neovascularization Market are focused continuously on the development of novel therapeutic approaches to address the unmet medical needs of patients with CNV. Leading Choroidal Neovascularization Market players are involved in clinical trials, research collaborations, and strategic partnerships to fortify their product portfolios and expand their market presence. The competitive Choroidal Neovascularization Market landscape is a mix of both established pharmaceutical companies and emerging biotechnology ventures. Novartis, Bayer, Roche, Regeneron, and Allergan are the key players in the Choroidal Neovascularization Market. These companies are spending on research and development activities to develop innovative therapies targeting the underlying cause of CNV and improve patient outcomes. The Choroidal Neovascularization Market has excellent growth potential in the upcoming years due to the growing prevalence of age-related macular degeneration and diabetic retinopathy and the development of novel therapeutic approaches. Novartis is one of the leading players in the Choroidal Neovascularization Market with a strong presence in ophthalmology. The company’s present portfolio includes Lucentis ranibizumab, which is a VEGF inhibitor approved for the treatment of wet age-related macular degeneration and other retinal diseases. Novartis has a robust pipeline of new therapies for CNV, including brolucizumab, a new drug showing superior effects in clinical trials. This new drug is also a strong contender for a blockbuster position in the near future. Novartis’ POS is high due to its strong commercial presence and commitment to innovation. Bayer is another prominent player in the Choroidal Neovascularization Market with a stronghold in ophthalmology. The company’s present portfolio includes Eylea aflibercept, a VEGF inhibitor approved for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other retinal diseases. The company's current drug being developed for CNV is farcical. The biggest strength of Bayer in the Choroidal Neovascularization Market is its strong product portfolio and commitment to Research and Development. ## Recent News & Developments Key factors driving this growth include the increasing prevalence of age-related macular degeneration (AMD), the leading cause of CNV, as well as advancements in treatment modalities such as anti-vascular endothelial growth factor (VEGF) therapies. Geographic regions with high geriatric populations, such as North America and Europe, are expected to hold significant market shares. Recent developments in the CNV market include the approval of novel anti-VEGF agents with improved efficacy and safety profiles, as well as the emergence of gene therapy approaches targeting the underlying genetic causes of CNV. ## Report Scope | MARKET SIZE 2024 | 1.916(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.043(USD Billion) | | MARKET SIZE 2035 | 3.887(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.64% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Amgen (US), Santen Pharmaceutical (JP), Eyenovia (US) | | Segments Covered | Treatment Type, Indication, Route of Administration, End User, Regional | | Key Market Opportunities | Advancements in gene therapy and biologics enhance treatment options in the Choroidal Neovascularization Market. | | Key Market Dynamics | Rising prevalence of age-related macular degeneration drives demand for innovative therapies in the Choroidal Neovascularization Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Choroidal Neovascularization Market by 2035?** A: The Choroidal Neovascularization Market is projected to reach a valuation of 3.887 USD Billion by 2035. **Q: What was the market valuation of the Choroidal Neovascularization Market in 2024?** A: In 2024, the overall market valuation was 1.916 USD Billion. **Q: What is the expected CAGR for the Choroidal Neovascularization Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Choroidal Neovascularization Market during the forecast period 2025 - 2035 is 6.64%. **Q: Which treatment type segment is projected to have the highest valuation by 2035?** A: The Anti-Angiogenic Therapy segment is projected to reach a valuation of 1.6 USD Billion by 2035. **Q: What are the key indications driving the Choroidal Neovascularization Market?** A: Key indications include Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), with AMD projected to reach 1.575 USD Billion by 2035. **Q: Which route of administration is expected to dominate the market by 2035?** A: The Intravitreal route of administration is expected to dominate, with a projected valuation of 1.956 USD Billion by 2035. **Q: What is the anticipated market performance of hospitals as an end user by 2035?** A: Hospitals are anticipated to reach a market valuation of 1.558 USD Billion by 2035. **Q: Who are the key players in the Choroidal Neovascularization Market?** A: Key players include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Amgen, Santen Pharmaceutical, and Eyenovia. **Q: What is the projected valuation for the Photodynamic Therapy segment by 2035?** A: The Photodynamic Therapy segment is projected to reach a valuation of 0.6 USD Billion by 2035. **Q: How does the market for Central Serous Chorioretinopathy (CSC) appear to be evolving?** A: The market for Central Serous Chorioretinopathy (CSC) is projected to grow to 0.575 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/choroidal-neovascularization-market-27541*